Mary Beth Harler - Jul 19, 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Head, Research & Autoimmunity
Signature
/s/ Misbah Tahir, by power of attorney
Stock symbol
IGMS
Transactions as of
Jul 19, 2024
Transactions value $
$0
Form type
4
Date filed
7/23/2024, 08:38 PM
Previous filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Award +55K +64.53% 140K Jul 19, 2024 Direct F1, F2
transaction IGMS Common Stock Award +25K +17.83% 165K Jul 19, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Stock Option (right to buy) Disposed to Issuer -200K -100% 0 Jul 19, 2024 Common Stock 200K $61.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on July 19, 2025 and one-eighth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
F2 Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 200,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 54,999 shares and 25,001 shares.
F3 These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on January 19, 2026 and one-twelfth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.